Armata Pharmaceuticals Reports Progress on AP-SA02 Phase 3 Study and Promotes David House to CFO

Armata Pharmaceuticals, Inc.

Submitted complete Phase 3 superiority protocol to FDA for AP-SA02, addressing all End-of-Phase 2 meeting comments.
Completed four engineering runs of AP-SA02 at cGMP facility; clinical trial material production is next step.
Received $2.5 million continuation award from DoD, bringing total funding to $28.7 million for Phase 3 readiness.
Promoted David House to Chief Financial Officer; he previously served as SVP, Finance since August 2024.
Phase 3 superiority study remains on track to initiate in the second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.